7,3′,4′-Trihydroxyisoflavone, a major metabolite of Daidzein, is an ATP-competitive inhibitor of Cot (Tpl2/MAP3K8) and MKK4. 7,3′,4′-Trihydroxyisoflavone has anticancer, anti-angiogenic, chemoprotective, and free radical scavenging activities^[1][2].

7,3′,4′-Trihydroxyisoflavone triggers cell cycle arrest at the G1 phase and displays an anti-proliferative effect against EGF receptor-positive skin cancer^[1].
7,3′,4′-Trihydroxyisoflavone also significantly inhibits UVB-induced COX-2 expression by suppressing the NF-B transcription activity in mouse skin epidermal JB6 P⁺ cells^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

In a mouse skin tumorigenesis model, 7,3′,4′-Trihydroxyisoflavone strongly suppresses the incidence, multiplicity, and volume of UVB-induced mouse skin tumors. Consistent with the tumor data, 7,3′,4′-Trihydroxyisoflavone clearly attenuates UVB-induced COX-2 expression in hairless mouse skin^[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

270.24

C₁₅H₁₀O₅

485-63-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yu-Li Lo, et al. 7,3′,4′-Trihydroxyisoflavone modulates multidrug resistance transporters and induces apoptosis via production of reactive oxygen species. Toxicology. 2012 Dec 16;302(2-3):221-32.

  [2]. Dong Eun Lee, et al. 7,3′,4′-Trihydroxyisoflavone, a metabolite of the soy isoflavone daidzein, suppresses ultraviolet B-induced skin cancer by targeting Cot and MKK4. J Biol Chem. 2011 Apr 22;286(16):14246-56.